Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI

ADGIAdagio Therapeutics, Inc. US flag

NASDAQ Global Market

4.64

USD

+0.04

- -

505.68MMarket Cap

Adagio Therapeutics, Inc.

ADGI

(NASDAQ Global Market)

Recent

price

4.64

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Legend Biotech Corporation (LEGN)
Oxford Nanopore Technologies plc (ONT.L)
Bellerophon Therapeutics, Inc. (BLPH)
Tarsus Pharmaceuticals, Inc. (TARS)
Haleos Labs Limited (HALEOSLABS.NS)
Adaptive Biotechnologies Corporation (ADPT)
Business: Adagio Therapeutics, Inc. (NASDAQ:ADGI), now operating as Invivyd, Inc. (NASDAQ:IVVD), is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential, particularly respiratory viruses including SARS-CoV-2, influenza, respiratory syncytial virus (RSV), and measles. The company offers a pipeline of monoclonal antibodies, with lead product PEMGARDA (pemivibart, previously derived from adintrevimab/ADG20), a half-life extended investigational monoclonal antibody authorized by the U.S. FDA under Emergency Use Authorization for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals; additional candidates include VYD2311, an investigational monoclonal antibody optimized for neutralizing contemporary SARS-CoV-2 lineages, VBY329, a potential best-in-class RSV antibody candidate targeting IND readiness in the second half of 2026, and discovery-stage programs for seasonal influenza, measles, and Long COVID via the SPEAR Study Group. Founded in 2020 and headquartered in Waltham, Massachusetts, the company leverages a proprietary integrated discovery platform to engineer antibodies that surpass natural immunity; it primarily serves immunocompromised and high-risk patient populations in the United States, with operations centered in North America. Recent developments include a corporate rebranding to Invivyd in September 2022 to reflect its expanded focus on viral respiratory threats beyond COVID-19, FDA Emergency Use Authorization for PEMGARDA in March 2024, a $125 million public offering priced in November 2025 to support VYD2311 commercialization and pipeline advancement, a $50 million public offering in August 2025 for clinical programs in RSV, measles, and Long COVID research, and selection of RSV candidate VBY329 in 2025; earlier efforts encompassed Phase 2/3 trials of adintrevimab and a February 2025 FDA refusal to expand PEMGARDA's EUA.

Company News